Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Influence of Opioid Agonists on Cardiac HumanEther-a-go-go-related Gene K+ Currents

Alexander N. Katchman, Kelly A. McGroary, Michael J. Kilborn, Craig A. Kornick, Paolo L. Manfredi, Raymond L. Woosley and Steven N. Ebert
Journal of Pharmacology and Experimental Therapeutics November 2002, 303 (2) 688-694; DOI: https://doi.org/10.1124/jpet.102.038240
Alexander N. Katchman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly A. McGroary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Kilborn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig A. Kornick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo L. Manfredi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond L. Woosley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven N. Ebert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We have evaluated the ability of various opioid agonists, including methadone, l-α-acetylmethadol (LAAM), fentanyl, meperidine, codeine, morphine, and buprenorphine, to block the cardiac human ether-a-go-go-related gene (HERG) K+current (IHERG) in human cells stably transfected with the HERG potassium channel gene. Our results show that LAAM, methadone, fentanyl, and buprenorphine were effective inhibitors of IHERG, with IC50 values in the 1 to 10 μM range. The other drugs tested were far less potent with respect to IHERG inhibition. Compared with the reported maximal plasma concentration (Cmax) after administration of therapeutic doses of these drugs, the ratio of IC50/Cmax was highest for codeine and morphine (>455 and >400, respectively), thereby indicating that these drugs have the widest margin of safety (of the compounds tested) with respect to blockade of IHERG. In contrast, the lowest ratios of IC50/Cmax were observed for LAAM and methadone (2.2 and 2.7, respectively). Further investigation showed that methadone block of IHERG was rapid, with steady-state inhibition achieved within 1 s when applied at its IC50 concentration (10 μM) for IHERG block. Results from “envelope of tails” tests suggest that the majority of block occurred when the channels were in the open and/or inactivated states, although ∼10% of the available HERG K+ channels were apparently blocked in a closed state. Similar results were obtained for LAAM. These results demonstrate that LAAM and methadone can block IHERG in transfected cells at clinically relevant concentrations, thereby providing a plausible mechanism for the adverse cardiac effects observed in some patients receiving LAAM or methadone.

Footnotes

  • ↵1 Current address: Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia, 2050.

  • ↵2 Current address: Mayo Clinic, Jacksonville, FL 32224.

  • This work was supported by a grant from the National Institutes of Health (R01-HL58743), Agency for Healthcare Research and Quality, Center for Education and Research on Therapeutics, HHS (U18 HS10385), and funds from the United States Food and Drug Administration. This work was presented, in part, as a late-breaking abstract at the Experimental Biology 2001 meeting in Orlando, FL, and also at the IUPHR XIVth World Congress of Pharmacology Meeting in San Francisco, CA (July 2002). Katchman AN, Ebert SN, McGroary KA, and Woosley RL (2001) Methadone blocks HERG current in transfected HEK cells.Pharmacologist43:98 (Abstract). Katchman AN, Woosley RL, and Ebert SN (2002) Comparative evaluation of opioid agonists on HERG K+ current. IUPHR XIVth World Congress of Pharmacology Meeting. San Francisco, CA (Abstract).

  • DOI: 10.1124/jpet.102.038240

  • Abbreviations:
    IKr
    delayed rectifier potassium current
    HERG
    human ether-a-go-go-related gene
    LAAM
    l-α-acetylmethadol
    IHERG
    cardiac humanether-a-go-go-related gene K+ current
    HEK
    human embryonic kidney
    EDDP
    2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
    • Received April 29, 2002.
    • Accepted July 2, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 303 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 303, Issue 2
1 Nov 2002
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Influence of Opioid Agonists on Cardiac HumanEther-a-go-go-related Gene K+ Currents
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Influence of Opioid Agonists on Cardiac HumanEther-a-go-go-related Gene K+ Currents

Alexander N. Katchman, Kelly A. McGroary, Michael J. Kilborn, Craig A. Kornick, Paolo L. Manfredi, Raymond L. Woosley and Steven N. Ebert
Journal of Pharmacology and Experimental Therapeutics November 1, 2002, 303 (2) 688-694; DOI: https://doi.org/10.1124/jpet.102.038240

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Influence of Opioid Agonists on Cardiac HumanEther-a-go-go-related Gene K+ Currents

Alexander N. Katchman, Kelly A. McGroary, Michael J. Kilborn, Craig A. Kornick, Paolo L. Manfredi, Raymond L. Woosley and Steven N. Ebert
Journal of Pharmacology and Experimental Therapeutics November 1, 2002, 303 (2) 688-694; DOI: https://doi.org/10.1124/jpet.102.038240
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Optimized S-nitrosohemoglobin synthesis in red blood cells
  • High-Salt Diet Upregulates CaSR Expression and Signaling
  • L-Arginine improves post-infarction physical function
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics